BioInvent: Preclinical data published in Cancer Cell highlight novel...

... with market exclusivity for treatment of multiple myeloma with an antibody against ICAM-1 for up to 10 years after marketing approval is granted. The F.I.R.S.T.TM screening system is based on BioInvent's n-CoDeR library and is a proprietary antibody ...

http://www.businesswire.com/news/topix/20130415006741/en